Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good question ... I'm on a similar quest to find value small caps having profitable track record, good valuation, with some sort of strategic niche ... these have always turned out to be my most consistent performers and research shows that small value stocks provide the best return.
What do you think about the preliminary India trial results that we were lead to believe were very positive? Is the science at least still potentially in favor? (Just curious as I have not got my head around this.)
Could there have been fraudulent fudging of the results?
I was always a little concerned that there was not a randomized control group so perhaps the trial was/is biased by some unknown factor.
Thanks for sharing that blog ... I had not seen it.
I think if they get provincial insurance approval such as OHIP (Ontario health insurance plan) then our VRS will take off. Otherwise, I agree we'll have to wait for FDA as the next potential catalyst.
If the test is not covered by insurance, few will want to bear the additional expense over a normal exam. And with few customers, few dermatologists will order the machine.
What red flags? I asked you what information you had and you said to 'wait and see'.
Now you pretend like you've shared information?
So when can we expect some news here? ... been very quiet!
If you call today's 3% move "plummetting", what will you call it when it goes up 3%?
Why would anyone believe you when you don't backup your thoughts with actual details?
Safeway, Albertsons ... all the largest customers about to come online!
EORBF/ORT.TO - Recent news that Veolia (300K employees across 77 countries) now has a board member. Remember that agreement that I posted a while back ... looks like some things are cooking behind the scenes.
Too bad about the calcinator needing to be upgraded and its delay and cost as well as the decimation of the venture exchange. Fundamentals otherwise the same and the whole sector should see a strong rebound at some point ...
Safeway has nearly 2000 locations ... I would think that getting all this shelf space would most certainly generate some significant sales lift. Why else would Safeway make such a commitment?
Are you saying that Safeway, in utilizing their precious shelf space, is ill-informed in its expectations? That's a pretty bold claim considering the decades experience and reach of this company.
Do you know something that Safeway product managers don't?
Didn't we go through this yesterday? ... what about Albertson's Safeway, etc?? These were only announced recently!
Didn't we go through this already last night? Why do you make these claims without backing them up?
I see two scenarios (1) you don't have any such knowledge/information and are just trying to provoke longs and/or fear (2) you do have some information but you have the personality type that enjoys misfortune in others so you'd rather not share just to laugh later (schadenfreude).
Either way, your response does not seem sincere and is not too helpful. Of course, if you have some explanation as to why you can't share this information now, I'm all ears...
I'm all ears ... and even if I don't believe you perhaps you'll benefit some of the lurkers.
What is your forecast given that Safeway, Albertsons, etc, have yet to come online? Are you expected a negigable impact? If so, why? What about this tactic?
If you'd rather insult me than answer my question, that does not lend much credibility to you.
Their largest customers (by far) were just recently announced -- such as Safeway and Albertsons -- so I'm eagerly anticipating for these revenue streams to come online.
Are you suggesting managment lied about these specific new customers? That's quite a serious accusation! Do you have some evidence to back up your claim?
Sorry, could not resist ... anyway, thanks for the info as always.
That's some impressive photo-shopping! (lol.)
DXM - a nice triple in a few months!! Looks like Glen might be right... also a double on ylwwf!
I sold today 1/2 ylwwf (warrants) to acquire ylwdf (common). Essentially my gains on the warrants are locked in as free shares. Hopefully the warrants will retrace.
Yellow Media: Sold 1/2 of my warrants (which have appreciated very nicely from 1.85 to 3.70) to purchase common shares ... trying to lock in some gains will not losing upside.
If warrants retrace or hold this level for while, I'll be looking to reaquire. If I'm lucky, will earn some extra on the volatility.
DXM doing very well too! Thanks again!!
Hopefully OHIP coverage comes soon as I think that is the issue.
I can't imagine most derms paying for this tech if customers can't use their insurance ... of course, longer-term this should work out.
PLSB "Pulse Provides 1st Quarter Results and Corporate Update"
http://finance.yahoo.com/news/pulse-provides-1st-quarter-results-130000252.html
DENVER, CO--(Marketwired - May 16, 2013) - The Pulse Beverage Corporation (OTCQB: PLSB) ("Pulse"), makers of PULSE® brand of functional beverages and Cabanaâ„¢ 100% Natural Lemonade, today announced its 1st Quarter results for 2013 and issued a corporate update.
Q1-2013 Highlights:
Case sales during Q1-2013 for Cabanaâ„¢ increased 169% quarter over quarter and 133% as compared to Q1-2012. Revenue during Q1-2013 for Cabanaâ„¢ increased by 232% quarter over quarter and 115% as compared to Q1-2012.
Pulse's Q1-2013 net loss from operations was expected and was a result of costs associated with improvements made to its flagship product PULSE®, expanding its distribution system, costs associated with securing chain store listings, cost and shipping of samples of both products to distributors and chain store buyers. Pulse expects to be operationally cash flow positive by the end of Q2-2013. We expect Cabanaâ„¢ to reach the annualized one million case threshold by the end of Q2-2013. This is a very meaningful accomplishment for Pulse as well-respected beverage publications generally report that it normally takes four to six years to reach corporate profitability and annualized one million case threshold for new beverage brands.
During Q1-2013 grocery and convenience store chain store listings for Cabanaâ„¢ increased by 4,000 listings to more than 11,000. An additional 2,000 chain store listings have been secured for Cabanaâ„¢ since March 31, 2013 to a total of 13,000. It generally takes four to five months between securing a listing and having product on the shelf for sale to consumers. Some of the more notable chains carrying, or committed to carrying, Cabanaâ„¢ are: Safeway Inc. including Vons and all banners, Sobeys (Canada), Albertsons, Walgreens, Whole Foods (selected divisions), Kroger (selected divisions), Hy-Vee, Roundy's Supermarkets, Hannaford and Sprouts. Pulse is in the process of securing many more chain store listings for both PULSE® and Cabanaâ„¢. Some of these will soon be carrying PULSE® as well.
Pulse has in excess of $4.5 million in working capital as at March 31, 2013 including cash of $3.8 million, as such, Pulse will likely not need additional capital to finance the growth of its operations for its PULSE® and Cabanaâ„¢ products. Pulse has received several offers for additional financing but has turned the offers down as it doesn't require additional financing for the foreseeable future.
PLSB - had a loss this Q, but Safeway, Walgreens and Albertsons were all announced too recently to be included ... still optimistic for the company as these customers ramp-up.
No panic or disappointment for me. They just announced Safeway in April, which is a massive account for them ... going to take another quarter or two to book revenues there.
Walgreens and Albertsons also have not had sufficient time either... big revenue growth still to come from -- by far -- all their largest customers.
The beautiful thing for longs is that, with a market cap of only $5M, what might be considered small news to the casual investor could indeed be explosive for HHSE.
Everything needs to be taken in context of the market cap.
I have no idea where we are going but an analyst on Bloomberg radio made an interesting comment I had not considered that you might find interesting. As you know, bond prices are at record lows where -- at some point eventually -- the Fed is going to have to reduce the massive monetary stimulous and start raising rates. At such time, bonds -- which are now at record highs -- could be in for a sustained and significant decline. Accordingly, stocks will become relatively more attractive thus driving up stock prices.
As long as no big fear-factor comes into play and we continue with sluggish growth, this scenario, I think could happen. Also, I think when markets hit record highs they tend to overshoot quite a bit so the historical trend is still in favor.
Of course, the market is *very* toppy right now so it would probably not be difficult for some adverse event, even a minor one, to spark fear back into the market.
Having thought through the above, I'm long-term bullish (3-4 years) but will look for a nice dip in the short to medium term (next 3-6 months).
Incidentally, for my retirement accounts, which have been exclusively stock-based mutual funds, for my first adjustment ever (over 10 years) I moved recently about 10% into 'capital presevation' to lock in some gains and take advantage of any upcoming dips.
PLSB "Pulse Increases California Coverage to 80% Through Six Distributors"
The Pulse Beverage Corporation (OTCQB: PLSB) ("Pulse"), makers of PULSE® brand of functional beverages and Cabanaâ„¢ 100% Natural Lemonade, today announced that it has secured four more distributors in the populous state of California. Coverage extends to more than 30 million of the 37 million residents. Pulse has completed its second run of its flagship product, PULSE®, and has begun shipping to Southern California.
Existing distributors are: Avanzar Sales and Distribution, covering Orange, LA, San Bernardino and Riverside counties; Geyser Distributing covering 14 counties including San Francisco and Alameda; Specialty Beverage Distributor covering San Diego and Imperial counties; G.B.L. Distributing Company covering Santa Barbara, Ventura and San Luis Obispo counties; Premium Beverage Company covering Santa Cruz and Monterey; and D&L Distributing.
Patrick Madden of Specialty Beverage, based out of San Diego, said, "We just started selling Cabanaâ„¢ and the reception and resulting sales have been outstanding. We are very excited to distribute Cabanaâ„¢ to our customers."
Bill Juarez, President of Avanzar, commented, "We are excited to further our partnership with Pulse to assist in the launch of PULSE® into the Southern California marketplace. The collaboration of Pulse and Baxter Labs is unique and in our 25+ years in the beverage industry we can't recall a brand that has come to market with the evolutionary combination of proven health benefits and great taste. We believe this new line of functional beverages will only add to the strength of the Cabanaâ„¢ brand which we currently represent for Pulse in the natural food channel as well as distribute in our DSD businesses in SoCal and soon to be in Arizona."
INO "Inovio Pharmaceuticals DNA Vaccine Against Ebola and Marburg Filoviruses Provides Complete Protection in Preclinical Challenge..."
http://ih.advfn.com/p.php?pid=nmona&article=57559559&symbol=INO
BLUE BELL, Pa., May 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon® DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccine induced strong and broad immune responses and demonstrated 100% protection against death following a challenge with multiple variants of the pathogen in two animal models.
There is no approved vaccine or therapy available against these highly virulent pathogens that have killed up to 90% of the people they infected. Because these viruses could potentially be easily transmitted, result in high mortality rates and cause a major public health impact, various agencies are seeking solutions for public health preparedness. A DNA vaccine could offer faster design and manufacturing timelines than traditional vaccine approaches, but particularly important, Inovio's SynCon® products offer the potentially preemptive advantage of enabling a design to provide broad protection encompassing multiple families of these so-called filoviruses.
Preclinical data was published in the peer-reviewed journal Molecular Therapy in a paper, "Induction of Broad Cytotoxic T Cells by Protective DNA Vaccination Against Marburg and Ebola," authored by Inovio researchers and collaborators.
Using Inovio's proprietary SynCon® design approach, Inovio researchers developed a polyvalent DNA vaccine consisting of three consensus plasmids to broadly target variant virus strains within three distinct families of Ebola and Marburg viruses. In the first part of this study, following two vaccinations using Inovio's proprietary CELLECTRA® electroporation device, 100% of vaccinated guinea pigs were protected from death following a virus challenge. The researchers observed significant increases in neutralizing antibody titers and strong and broad levels of vaccine-induced T-cells, including "killer" T-cells, and subsequently conducted a test in mice using only one vaccination – this single dose also fully protected the animals from death following a virus challenge. In addition, unlike the non-vaccinated animals, vaccinated animals were protected from weight loss.
Dr. Joseph Kim, Inovio's President and CEO said, "This study again demonstrates the preventive potency and broad immune response that we consistently see in studies of our DNA portfolio of vaccines. These immune response characteristics are the type considered necessary to achieve protection in humans. These outstanding results support Inovio's active biodefense program, which has garnered multiple grants from the Department of Defense, Defense Threat Reduction Agency (DTRA), National Institute of Allergy and Infectious Diseases (NIAID), and other government agencies focused on public health which value our DNA vaccine approach to treating and preventing disease."
About Inovio Pharmaceuticals, Inc.
that guy making those reduculous criticisms has dissappeared, so I'm happily waiting. One question I have for the board here is details about the process in canada for insurance coverage for the tests to be approved.
that guy making those reduculous criticisms has dissappeared, so I'm happily waiting. One question I have for the board here is details about the process in canada for insurance coverage for the tests to be approved.
Hi Glen - I don't have much to add but feel sorry for you being all alone ... lol!
My returns are already more than 100% so thanks brining my attention here!
Sold around 8 cents (I think and) missed the run ... at one point I was down about 50% so I'm happy to at least have made a positive return ...
Yes, and due to the lack of selling volume anyone wishing to buy is going to have to push the price up!!
Since Cowboys and Vampires is seemingly available from three distributors, is that in the context of below? If so, might make sense as the other distributors probably cannot sell in Walmart....
3). MULTI-STUDIO DISTRIBUTION PACT -- We have discussed in prior disclosures and blogs that the Company is structuring an exciting "multi-studio" distribution pact. To meet late Summer / early Fall release slots, a major effort is underway to conclude this structure within the next two weeks (if it's going to happen); while Hannover House is happy with our current distribution conduit structures (both direct and through two-step wholesalers), we feel that the new structure as proposed could result in a 2X or greater improvement in overall sales... so it's absolutely been a major priority of the management time invested.
VRSEF - That was interesting that there is essentially one remaining hurdle: coverage by insurance companies. Of course, it does not seem this would be a long-term issue and also would explain if sales are not (yet) to high. I bought some more yesterday.
I wonder how long it generally takes to get this approval?
Also intersting that nurses, not the doctor, administer the exam. Not sure this was discussed before, but that is an additional benefit.
ADXS - I'm trying to investigate more into intepretting these results. Below is an interesting response from yahoo. Has anyone read or can anyone locate this 'RL Paper'? I believe it is 'RL Capital' but I can't find anything on their webpage.
If the details below can be confirmed, I might reload at hopefully a lower price (once the 30-day wash sale expires).
********************************************
"I'm trying to get my head around this. If, for assumption purposes, the treatment is effective at boosting the immune system to treat cancer, shouldn't the treatment also be effective at boosting the immune system to prevent cancer? Or does the immune system, in these cases, function fundamentally differently?"
**
"Stills thats the core of the issue, if you read the RL paper there is a definite difference when confronted with active vs dormant scenarios- l recommend everyone to do it -. Looks like Listeria is a good approach for metastatic scenarios.
We all assume the same that if good for one, good for the other, however it does not look that way. Of course the low dose use could be the main issue but maybe not.
The point for me is that enough of shooting all over the place...concentrate on the cancer approach, specially late stage metastatic scenarios go for maximum possible dose and let it rip. Of course MGMT should man up for their mistakes. They need to show they believe in the science, they believe in the company and clearly state their strategy going forward."
ADXS - sold 1/2 @ .0547.
The rest of the shares could still be very profitable but I'm not comfortable to interpret the significance of these results in terms of the overall pipeline. Also, although arguably not the most important trial, I put a little more weight into the US trial because of the randomized test design.
ADXS - US CIN results did not show efficacy (but could be due to low-dosage).
I'm not sure if this reduces the probability of success in the India trials??
http://filings.irdirect.net/data/1100397/000114420413025277/v343327_defa14a.pdf
Could be a sell-off today, sell-off and bounceback, or perhaps this bad news is already baked-in ...
Ageed, although I don't need to be conviced that Michael is reasonable guy!
I'm struggling what to think so pretty much any explanation these days seems reasonable, however. Despite the greater uncertainty of HHSE missing their deadlines is also a lower share price and thus, greater opportunity so I'm still holding. The stakes are getting higher and higher!
If I see TITA in walmart or the SEC preview, I'll certainly buy more if these prices hold.
The continually squashed expectations are getting to me so just needed to blow off some steam ... I'm better now! Thanks for the input Wadi!
Thanks Michael ... this wait is getting soooooo tiresome but it's good to be updated where everyone is at.
I guess the truth has to come out eventually, so some drama (with extreme movement one way or the other) will certainly break this monotony some point not too long from now.